Cargando…
Lysophosphatidic Acid Receptor 5 (LPAR5) Plays a Significance Role in Papillary Thyroid Cancer via Phosphatidylinositol 3-Kinase/Akt/Mammalian Target of Rapamycin (mTOR) Pathway
BACKGROUND: Thyroid cancer is the most common endocrine system malignancy. Scientists have done considerable research into the molecular mechanisms involved, but many mechanisms remain undiscovered. MATERIAL/METHODS: We performed a comprehensive analysis of the whole-transcriptome resequencing deriv...
Autores principales: | Wu, Cheng-Yong, Zheng, Chen, Xia, Er-Jie, Quan, Rui-Da, Hu, Jing, Zhang, Xiao-Hua, Hao, Ru-Tian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
International Scientific Literature, Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6977615/ https://www.ncbi.nlm.nih.gov/pubmed/31902939 http://dx.doi.org/10.12659/MSM.919820 |
Ejemplares similares
-
Ursolic Acid Attenuates High Glucose-Mediated Mesangial Cell Injury by Inhibiting the Phosphatidylinositol 3-Kinase/Akt/Mammalian Target of Rapamycin (PI3K/Akt/mTOR) Signaling Pathway
por: Wang, Er-Min, et al.
Publicado: (2018) -
Everolimus Reverses Palbociclib Resistance in ER+ Human Breast Cancer Cells by Inhibiting Phosphatidylinositol 3-Kinase(PI3K)/Akt/Mammalian Target of Rapamycin (mTOR) Pathway
por: Chen, Lin, et al.
Publicado: (2019) -
Antiproliferative Activity of Carnosic Acid is Mediated via Inhibition of Cell Migration and Invasion, and Suppression of Phosphatidylinositol 3-Kinases (PI3K)/AKT/Mammalian Target of Rapamycin (mTOR) Signaling Pathway
por: Zhao, Liqun, et al.
Publicado: (2019) -
Girinimbine Inhibits the Proliferation of Human Ovarian Cancer Cells In Vitro via the Phosphatidylinositol-3-Kinase (PI3K)/Akt and the Mammalian Target of Rapamycin (mTOR) and Wnt/β-Catenin Signaling Pathways
por: Xin, Qiu, et al.
Publicado: (2018) -
Eriocalyxin B Induces Apoptosis and Autophagy Involving Akt/Mammalian Target of Rapamycin (mTOR) Pathway in Prostate Cancer Cells
por: Yu, Ziqiang, et al.
Publicado: (2019)